^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Undisclosed anti-KRAS G12D mTCR PBL
i
Other names: Undisclosed anti-KRAS G12D mTCR PBL
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Gilead, National Cancer Institute - Bethesda
Drug class:
KRAS inhibitor, T lymphocyte replacement
Related drugs:
